Showing results (91-100 of 288) with videos related to

Sort By:
Pageof 29
Immunobiology|August 22, 2006
Mphi1 and Mphi2 can be re-polarized by Th2 or Th1 cytokines, respectively, and respond to exogenous danger signalsAlexei Gratchev, Julia Kzhyshkowska, Kirsten Köthe, et al.
Leukemia Research|November 24, 2005
Additional Her 2/neu gene copies in patients with Sézary syndromeJochen Utikal, Nina Poenitz, Alexei Gratchev, et al.
International Journal of Cancer|October 30, 2014
Elevated chronic inflammatory factors and myeloid-derived suppressor cells indicate poor prognosis in advanced melanoma patientsHuanhuan Jiang, Christoffer Gebhardt, Ludmila Umansky, et al.
Sexual & Reproductive Healthcare : Official Journal of the Swedish Association of Midwives|February 23, 2013
Risk factors for Chlamydia trachomatis infection among users of an internet-based testing service in SwedenMasuma Novak, Daniel Novak
Cancer Letters|April 6, 2016
MicroRNAs as novel targets and tools in cancer therapyMohammed L Abba, Nitin Patil, Jörg H Leupold, et al.
Frontiers in Immunology|June 27, 2018
Myeloid-Derived Suppressor Cells Hinder the Anti-Cancer Activity of Immune Checkpoint InhibitorsRebekka Weber, Viktor Fleming, Xiaoying Hu, et al.
Frontiers in Immunology|March 20, 2018
Targeting Myeloid-Derived Suppressor Cells to Bypass Tumor-Induced ImmunosuppressionViktor Fleming, Xiaoying Hu, Rebekka Weber, et al.
Journal of Cutaneous Pathology|September 16, 2006
Cutaneous leiomyosarcoma with myxoid alteration arising in a setting of multiple cutaneous smooth muscle neoplasmsJochen Utikal, Georg Haus, Nina Poenitz, et al.
Cellular Immunology|December 9, 2020
IL-6 as a major regulator of MDSC activity and possible target for cancer immunotherapyRebekka Weber, Christopher Groth, Samantha Lasser, et al.
Oncoimmunology|August 18, 2023
Melanoma patients with immune-related adverse events after immune checkpoint inhibitors are characterized by a distinct immunological phenotype of circulating T cells and M-MDSCsAlisa Lepper, Rebekka Bitsch, Feyza Gül Özbay Kurt, et al.
Pageof 29